Apollomics Valuation
| APLM Stock | 20.80 0.55 2.72% |
At this time, the firm appears to be overvalued. Apollomics Class A shows a prevailing Real Value of USD10.36 per share. The current price of the firm is USD20.8. Our model approximates the value of Apollomics Class A from analyzing the firm fundamentals such as Operating Margin of 10.07 %, return on equity of -2.34, and Shares Outstanding of 2.14 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Apollomics' valuation include:
Price Book 8.1226 | Enterprise Value | Enterprise Value Ebitda (0.1) | Price Sales 6.263 | Enterprise Value Revenue 4.955 |
Overvalued
Today
Please note that Apollomics' price fluctuation is risky at this time. Calculation of the real value of Apollomics Class A is based on 3 months time horizon. Increasing Apollomics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Apollomics stock is determined by what a typical buyer is willing to pay for full or partial control of Apollomics Class A. Since Apollomics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Apollomics Stock. However, Apollomics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 20.8 | Real 10.36 | Target 2.0 | Hype 19.96 | Naive 25.57 |
The intrinsic value of Apollomics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Apollomics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Apollomics Class A helps investors to forecast how Apollomics stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Apollomics more accurately as focusing exclusively on Apollomics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Apollomics' intrinsic value based on its ongoing forecasts of Apollomics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Apollomics' closest peers.
Apollomics Cash |
|
Apollomics Total Value Analysis
Apollomics Class A is presently expected to have valuation of 42.12 M with market capitalization of 44.92 M, debt of 966 K, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Apollomics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
42.12 M | 44.92 M | 966 K |
Apollomics Investor Information
The company recorded a loss per share of 52.8. Apollomics Class A had not issued any dividends in recent years. The entity had 1:100 split on the 25th of November 2024. Based on the key indicators related to Apollomics' liquidity, profitability, solvency, and operating efficiency, Apollomics Class A is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February.Apollomics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Apollomics has an asset utilization ratio of 1.51 percent. This suggests that the Company is making USD0.0151 for each dollar of assets. An increasing asset utilization means that Apollomics Class A is more efficient with each dollar of assets it utilizes for everyday operations.Apollomics Ownership Allocation
The market capitalization of Apollomics Class A is USD44.92 Million. Almost 99.33 percent of Apollomics outstanding shares are held by general public with 0.67 % by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Apollomics Profitability Analysis
The company reported the previous year's revenue of 198 K. Net Loss for the year was (53.86 M) with profit before overhead, payroll, taxes, and interest of 198 K.About Apollomics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Apollomics Class A. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Apollomics Class A based exclusively on its fundamental and basic technical indicators. By analyzing Apollomics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Apollomics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Apollomics. We calculate exposure to Apollomics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Apollomics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 227.7 K | 216.3 K | |
| Pretax Profit Margin | (311.31) | (326.87) | |
| Operating Profit Margin | (191.53) | (201.10) | |
| Net Loss | (244.81) | (257.05) |
Apollomics Current Valuation Indicators
Apollomics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Apollomics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Apollomics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Apollomics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Apollomics' worth.When determining whether Apollomics Class A is a strong investment it is important to analyze Apollomics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Apollomics' future performance. For an informed investment choice regarding Apollomics Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Apollomics Class A. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apollomics. If investors know Apollomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apollomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (52.80) | Revenue Per Share | Quarterly Revenue Growth 2.623 | Return On Assets | Return On Equity |
The market value of Apollomics Class A is measured differently than its book value, which is the value of Apollomics that is recorded on the company's balance sheet. Investors also form their own opinion of Apollomics' value that differs from its market value or its book value, called intrinsic value, which is Apollomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apollomics' market value can be influenced by many factors that don't directly affect Apollomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apollomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Apollomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apollomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.